Hansoh Pharma (03692): The second application for the market authorization of Xinyue (Inolimomab monoclonal antibody injection) has been accepted by the National Medical Products Administration.

04/03/2025

GMT Eight

Hansoh Pharma (03692) announced that on March 4, 2025, the second Biologics License Application (BLA) for the innovative drug Xinyue (Enalizumab injection) has been accepted by the National Medical Products Administration (NMPA) for the treatment of Immunoglobulin G4-related diseases (IgG4-RD). On February 8, 2025, this indication was granted priority review and approval by the NMPA.

Shanghai Pharmaceuticals Holding (02607): The 2019 A-share stock option incentive plan has granted a total of 6.9768 million stock options for the third exercise period.

Wuhan Raycus Fiber Laser Technologies (300747.SZ) plans to distribute a cash dividend of 0.32 yuan per share on March 11 after the ex-dividend date.

Contact: contact@gmteight.com

Hansoh Pharma (03692): The second application for the market authorization of Xinyue (Inolimomab monoclonal antibody injection) has been accepted by the National Medical Products Administration.

RECOMMEND

PRADA (01913) will distribute a final dividend of 0.164 euro per share on May 19th.

A-share announcement selection | BYD Company Limited plans to issue new H-shares for fundraising of HK $43.5 billion Orient Group Incorporation (600811.SH) warns of the risk of delisting.

Hongjing Optoelectronics (301479.SZ) online pricing issue final winning rate is 0.0164%